Heparin - A Century of Progress

  • Rebecca Lever
  • Barbara Mulloy
  • Clive P. Page

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 207)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Introduction

    1. Front Matter
      Pages 1-1
    2. T. W. Barrowcliffe
      Pages 3-22
    3. Pernilla Carlsson, Lena Kjellén
      Pages 23-41
    4. Elaine Gray, John Hogwood, Barbara Mulloy
      Pages 43-61
  3. Unfractionated and Low-Molecular-Weight Heparins

    1. Front Matter
      Pages 63-63
    2. Edward K. Chess, Shawn Bairstow, Shane Donovan, Karalyn Havel, Peifeng Hu, Richard J. Johnson et al.
      Pages 99-125
    3. Zachary Shriver, Ishan Capila, Ganesh Venkataraman, Ram Sasisekharan
      Pages 159-176
  4. Clinical Use of Heparin and LMWH

    1. Front Matter
      Pages 177-177
    2. S. Alban
      Pages 211-263
    3. Menaka Pai, Mark A. Crowther
      Pages 265-277
  5. Non-anticoagulant Indications for Heparin and Related Compounds

    1. Front Matter
      Pages 279-279
    2. Rebecca Lever, Clive P. Page
      Pages 281-305
    3. B. Dudas, K. Semeniken
      Pages 325-343
  6. Heparin-like Entities

    1. Front Matter
      Pages 345-345
    2. J. T. Gallagher
      Pages 347-360
    3. Deirdre R. Coombe, Warren C. Kett
      Pages 361-383
    4. Luigi Allegra, Sabrina Della Patrona, Giuseppe Petrigni
      Pages 385-401
    5. P. Oreste, G. Zoppetti
      Pages 403-422
    6. S. Colliec-Jouault, C. Bavington, C. Delbarre-Ladrat
      Pages 423-449
  7. Back Matter
    Pages 451-459

About this book


Heparins remain amongst the most commonly used drugs in clinical practice.  Almost 100 years have passed since the initial discovery of this complex substance and, during this time, understanding of the nature and uses of heparin and related molecules has grown dramatically. The aim of this volume is to summarise the developments that have led to the current status of both heparins as drugs and the field of heparin research, with a focus on the particularly rapid progress that has been made over the past three decades. Individual sections are dedicated to the nature of heparin as a biological molecule, the current approaches and techniques that are used to ensure the safety and reliability of heparin as a medicine, the clinical pharmacology of heparin as an anticoagulant drug, effects and potential applications of heparin aside of those involving haemostasis and, finally, the nature and potential uses of heparin-like materials from both natural and synthetic sources.


Anticoagulants Biological Standardisation Glycosaminoglycan Heparin-binding Protein Physicochemical characterisation Thrombosis

Editors and affiliations

  • Rebecca Lever
    • 1
  • Barbara Mulloy
    • 2
  • Clive P. Page
    • 3
  1. 1.School of PharmacyUniversity of LondonLondonUnited Kingdom
  2. 2.Standards and ControlNational Institute for BiologicalPotters Bar, Herts.United Kingdom
  3. 3.King's College LondonSackler Inst. Pulmonary PharmacologyLondonUnited Kingdom

Bibliographic information

Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods